|Liquid Biopsy Market to Grow at a CAGR of 23.4% by 2022|
|By: PR Newswire Association LLC. - 27 Sep 2017||Back to overview list
PUNE, India, September 27, 2017 /PRNewswire/ --
The global liquid biopsy market is forecast to reach $2,047.9 million by 2022 from $715.7 million in 2017 at a CAGR of 23.4% during (2017-2022) driven by the increasing prevalence of cancer, increasing preference for noninvasive procedures, initiatives undertaken by government and global health organizations, technological advancement to augment market revenues, rising emphasis on personalized medicine, and availability of funding for liquid biopsy R&D according to RnRMarketResearch.
Browse 133 Market Data Tables and 44 Figures spread through 204 Pages and in-depth TOC on "Liquid Biopsy Market Global Forecast to 2022" http://www.rnrmarketresearch.com/liquid-biopsy-market-by-cancer-type-lung-breast-colorectal-prostate-liver-circulating-biomarkers-circulating-tumor-cells-circulating-tumor-dna-product-instruments-software-end-user-reference-laborato-st-to-2021-market-report.html.
North America is expected to account for the largest share of the global liquid biopsy market in 2017, while Asia Pacific is expected to witness the highest growth during 2017 to 2022. Growing demand for non-invasive treatment, rising incidence of cancer, and improving healthcare infrastructure are driving the growth of the liquid biopsy market.
The major market players in the liquid biopsy market are QIAGEN N.V. (Netherlands), Roche Diagnostics (US), Bio-Rad Laboratories Inc. (US), Myriad Genetics, Inc. (US), Menarini Silicon Biosystems (Italy), Genomic Health, Inc. (US), Thermo Fisher Scientific Inc. (US), Illumina, Inc. (US), Biocept, Inc. (US), Trovagene, Inc. (US), Guardant Health, Inc. (US), RainDance Technologies, Inc. (US), and MDxHealth SA (US).
Order a copy of Liquid Biopsy Market by Cancer Type (Lung, Breast, Colorectal, Prostate), Circulating Biomarkers (Circulating Tumor Cells, Circulating Tumor DNA, Cell-Free DNA), Product (Instruments, Assay Kits), End User (Reference Laboratory) - Global Forecast to 2022 research report at http://www.rnrmarketresearch.com/contacts/purchase?rname=640498.
Based on application, the liquid biopsy market is segmented into cancer and non-cancer applications (which include reproductive health and organ transplant diagnostics). The non-cancer application segment is expected to be the fastest-growing segment in the market during the forecast period. This is due to the growing application in noninvasive prenatal testing (NIPT), using cell-free DNA assays in the identification of trisomies (which includes 13, 16, and 18), gender identification, and other genetic abnormalities such as monosomy X and microdeletions. NIPT is also rapidly replacing amniocentesis in high-risk pregnancies, thus expanding its application.
The extracellular vesicles to register the highest CAGR of liquid biopsy market during the forecast period. Based on circulating biomarkers the market is categorized into circulating tumor cells (CTCs), circulating tumor DNA (ctDNA), cell-free DNA (cfDNA), extracellular vesicles (EVs) and other circulating biomarkers. The extracellular vesicles segment is the fastest-growing segment in the circulating biomarkers market during the forecast period. This is due to the growing interest in EV research from biofluids such as the blood and urine of cancer patients as a means of disease diagnosis and therapeutic monitoring.
Make an Inquiry on "Liquid Biopsy Market Global Forecast to 2022" research report at http://www.rnrmarketresearch.com/contacts/inquire-before-buying?rname=640498.
Break of primary participants was as mentioned below:
The report analyzes the liquid biopsy market and aims at estimating market size and future growth potential of this market based on various segments such as by product, circulating biomarker, clinical application, application, end user, and region. The report also includes competitive analysis of the key players in this market along with their company profiles, product offerings, recent developments, and key market strategies.
Another research titled Biopsy Devices Market Global Forecast to 2022 says, the global biopsy devices market is projected to reach $2.42 billion by 2022 from $1.74 billion in 2017, at a CAGR of 6.8% during the forecast period. The needle-based biopsy instruments segment is expected to grow at the fastest rate during the forecast period. The breast biopsy segment dominated the biopsy devices market in 2016. Stereotactic-guided biopsy segment to witness the highest growth during the forecast period. APAC to witness the highest growth during the forecast period. Companies such as C. R. Bard, Inc. (U.S.), Becton, Dickinson and Company (U.S.), Cook Group Incorporated (U.S.), Devicor Medical Products, Inc., (Leica Biosystems) (Germany), Argon Medical Devices (U.S.), B. Braun Melsungen AG (Germany), Cardinal Health, Inc. (U.S.), Olympus Corporation (Japan), Boston Scientific Corporation (U.S.), FUJIFILM Holdings Corporation (Japan), INRAD, Inc. (U.S.), Medtronic plc (Ireland) have been profiled in this 219 pages research report available at http://www.rnrmarketresearch.com/biopsy-devices-market-by-product-core-needle-biopsy-aspiration-biopsy-vacuum-assisted-biopsy-application-breast-biopsy-lung-biopsy-prostate-biopsy-guidance-stereotactic-ultrasound-by-end-user-hospital-st-to-2022-market-report.html.
Explore more reports on Healthcare Market at http://www.rnrmarketresearch.com/reports/life-sciences/healthcare.
RnRMarketResearch.com is your single source for all market research needs. Our database includes 100,000+ market research reports from over 95 leading global publishers & in-depth market research studies of over 5000 micro markets. With comprehensive information about the publishers and the industries for which they publish market research reports, we help you in your purchase decision by mapping your information needs with our huge collection of reports.
Connect with Us:
Copyright 2017 PR Newswire Association LLC.
|Back to overview list|